RGC (Regencell Bioscience Holdings) EPS (Basic): $-0.02 (TTM As of Dec. 2025)


RGC Regencell Bioscience Holdings Ltd RGC
34 GF Score
Price $7.45
! 2 Warning Signs
View Full Analysis

What is Regencell Bioscience Holdings EPS (Basic)?

Regencell Bioscience Holdings RGC -12.97% 34 EPS (Basic) is $-0.02 as of Dec. 2025. GuruFocus rates RGC with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Regencell Bioscience Holdings's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.02.

Regencell Bioscience Holdings's EPS (Diluted) for the six months ended in Dec. 2025 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.02.

Regencell Bioscience Holdings's EPS without NRI for the six months ended in Dec. 2025 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.02.

During the past 3 years, the average EPS without NRI Growth Rate was 22.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -30.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Regencell Bioscience Holdings's highest 3-Year average EPS without NRI Growth Rate was 22.40% per year. The lowest was -146.60% per year. And the median was -62.95% per year.

Regencell Bioscience Holdings  (NAS:RGC) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Regencell Bioscience Holdings EPS (Basic) Related Terms

Regencell Bioscience Holdings EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Regencell Bioscience Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings EPS (Basic) Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial -0.00 -0.02 -0.01 -0.01 -0.01

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.01 -0.00 -0.00 -0.01
RGC
34GF Score
Regencell Bioscience Holdings Ltd RGC
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regencell Bioscience Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Regencell Bioscience Holdings's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.584-0)/494.489
=-0.01

Regencell Bioscience Holdings's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-5.318-0)/494.489
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.02 mean?
Regencell Bioscience Holdings (RGC) has a EPS (Basic) of $-0.02 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Regencell Bioscience Holdings and its competitors.
Is Regencell Bioscience Holdings' EPS (Basic) too high?
Regencell Bioscience Holdings' current EPS (Basic) is $-0.02. Overall, Regencell Bioscience Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' EPS (Basic) compare to ELAN and NBIX?
Regencell Bioscience Holdings' EPS (Basic) of $-0.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Regencell Bioscience Holdings and its competitors. Regencell Bioscience Holdings's current EPS (Basic) is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current EPS (Basic) of $-0.02. The current EPS (Basic) is $-0.02. Regencell Bioscience Holdings' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current EPS (Basic) is $-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regencell Bioscience Holdings Business Description

Address 29 Leighton Road, 9th Floor, Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
34GF Score

Get the complete analysis for RGC

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price